<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282139</url>
  </required_header>
  <id_info>
    <org_study_id>TSARIP703 / WIRB #20031378</org_study_id>
    <secondary_id>00040256/00042966</secondary_id>
    <nct_id>NCT00282139</nct_id>
  </id_info>
  <brief_title>Aripiprazole in the Treatment of Tourette's Syndrome</brief_title>
  <official_title>Aripiprazole in the Treatment of Tourette's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <brief_summary>
    <textblock>
      This is an open-label, flexible dose study designed to evaluate the safety and efficacy of
      aripiprazole in TS (or chronic tic disorder) subjects with or without associated OC symptoms
      and with or without ADHD symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, flexible dose study designed to evaluate the safety and efficacy of
      aripiprazole in TS (or chronic tic disorder) subjects with or without associated OC symptoms
      and with or without ADHD symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global improvement in severity of symptoms (tic behaviors)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of behavior (improvement and severity) for co-morbid conditions, OCD and/or ADHD</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tourette's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DSM-IV primary diagnosis of Tourette's syndrome or chronic tic disorder;

        &quot;Moderate&quot; severity as reflected on the CGI or the YGTSS;

        Normal ECG; and,

        Written informed consent/assent.

        Exclusion Criteria:

        Female subjects of childbearing potential who are not practicing an effective method of
        birth control (including abstinence);

        Subjects who are pregnant or nursing women;

        Subjects with known seizure disorder, a history or seizures or with conditions that lower
        seizure threshold;

        Subjects who currently meet DSM-IV criteria for: Schizophrenia, Schizoaffective Disorder,
        Delusional Disorder, or Psychotic Disorder Not Otherwise Specified;

        Subjects with a Psychoactive Substance Abuse disorder (within the past 3 months);

        Subjects with known allergy or hypersensitivity to aripiprazole;

        Subjects who have any depot neuroleptic within one treatment cycle or any other changes in
        psychoactive medications (with the exception of antidepressants) in one month and two
        months for antidepressants prior to study entry for first administration of study
        medication;

        Subjects who have clinically significant abnormalities based on physical examination,
        medical history, ECG, or laboratory tests; and,

        Subjects on medication that pose drug interaction potential with aripiprazole such as
        carbamazepine, ketoconazole, paroxetine, and fluoxetine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tanya K Murphy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

